On 24 June 2026, the European Medicines Agency (EMA) officially confirmed that A1EA meets all the criteria to become an eligible patients’ and consumers’ organisation, marking an important milestone in the Alliance’s development and recognition at the European level.
As an eligible organisation, A1EA will be included in the EMA’s network of patients’ and consumers’ organisations and could get invited to actively participate in the Agency’s regulatory activities. This recognition may open new opportunities for A1EA to contribute to discussions that shape the development, evaluation and monitoring of medicines in Europe.
Eligible organisations receive targeted communications and consultation opportunities from the EMA and also help identify patient experts for product-specific regulatory activities. This ensures that the patient’s perspective is better represented throughout the medicine’s lifecycle.
A vision realised
When A1EA was founded in October 2024, one of the Alliance’s strategic goals was to become a recognised partner of the European Medicines Agency. After two years of building the organisation, meeting the eligibility requirements and preparing and publishing the necessary documentation, that vision has now become a reality.
This achievement reflects the dedication of the Board, member organisations and everyone who has contributed to establishing A1EA as a credible and trusted European patient alliance.
“I hope our efforts at EMA will further strengthen our position with policymakers and partners in the pharmaceutical industry and help us advocate even more effectively for the Alpha-1 community.”
Looking ahead
Becoming an EMA-eligible organisation is more than a recognition—it is an opportunity to ensure that the voices of people living with Alpha-1 Antitrypsin Deficiency are heard where important regulatory decisions are made.
A1EA looks forward to working closely with the EMA and other stakeholders to advance patient-centred medicines development and improve outcomes for the Alpha-1 community across Europe.
